Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Patients With Prostate Cancer.

NCT06922903 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

240

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: INR101

Sponsor

Yunhe Pharmaceutical (Tianjin) Co., Ltd